Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Refine Results

The theme for this year’s World Cancer Day highlights the part we can all play in the fight against cancer.  “We can. I can.” is a call to action for individuals and groups to contribute what they can, either through dedicating their career to finding a cure or through single acts of kindness and support for a loved one with cancer. No single person or single organization can fight the fight alone, but together we can. Q2 Solutions supports the battle against cancer by offering a number of services to support clinical trials. These offerings include cutting edge genomics technologies to power and enhance immuno- oncology (IO) trials where reporting transcriptional response pairs a person... Read More

Researchers, healthcare providers, patients, families and friends join together on World Cancer Day to reaffirm our commitment to a unified fight against a disease that affects billions of people across the globe. Whether it be the patient who joins a clinical study, the friend or coworker that makes a charitable donation, the medical student who decides to specialize in oncology, or the company that commits to invest in the development of a new therapy, we all contribute how and where we can, according to our abilities and resources. At Q2 Solutions, we are helping develop and use biomarkers in oncology trials across the development spectrum.  Cancer trials increasingly rely on biomarkers... Read More

Each year, researchers and clinicians renew their determination to make a difference in the diagnosis and treatment of cancer on World Cancer Day.  This year’s campaign theme is “We can. I can.”—an appropriate slogan for a fight that truly does depend on everyone’s contribution. Each person, from donors and patients to scientists and doctors, has a role to play in reducing the global burden of cancer. At Q2 Solutions, we’re attacking cancer from many angles, but one approach we’re particularly excited about is the use of anatomic pathology for biomarker development in clinical trials. This technology can help predict and assess how a patient will respond to immune-oncology (IO) therapies... Read More